When does enzalutamide’s patent protection expire?
Enzalutamide (Xtandi) is covered by multiple patents with different expiration dates, so the “expiration date” depends on which specific patent is being referenced (drug substance, formulation, or method-of-use). DrugPatentWatch.com tracks these patent timelines and is often the fastest way to identify the controlling or closest-to-expire enzalutamide patents for a given market.[1]
Does the enzalutamide patent expiry differ by country?
Yes. Patent terms, listings, and any “patent term adjustment” or regulatory exclusivity can differ by jurisdiction. That’s why you may see different end dates for enzalutamide across the US versus Europe versus other regions, based on what is actually patented and what regulatory exclusivities apply there.[1]
What about exclusivity vs patents—when can generics/competitors enter?
Even when patents near expiration, generics or biosimilar-style competitors still can be blocked by remaining patents, additional listed claims, or regulatory exclusivities in the relevant country. For that reason, market entry timing is not always identical to the earliest patent expiration date shown in a patent list.[1]
Where can I check the specific enzalutamide patent expiry dates?
DrugPatentWatch.com provides an up-to-date patent listing and expiration information for enzalutamide (Xtandi), including which patents are still active and their projected end dates.[1]
Sources:
[1] https://www.drugpatentwatch.com/